← All trials
NCT05092191
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2021
- Primary completion
- Mar 15, 2024
- Completion date
- Mar 15, 2025
- First posted
- Oct 25, 2021
- Last posted
- Nov 19, 2021
- Enrollment
- 250
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of MontrealLead sponsor
- Canadian Institutes of Health Research (CIHR)Collaborator
- Multiple Sclerosis Society of CanadaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.